No Data
No Data
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
Positive Outlook on Elevation Oncology: Anticipating EO-3021 Data Release Impact
Piper Sandler Maintains Elevation Oncology(ELEV.US) With Buy Rating, Maintains Target Price $10
Express News | JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
TD Cowen Maintains Elevation Oncology(ELEV.US) With Buy Rating
JMP Securities Maintains Elevation Oncology(ELEV.US) With Buy Rating, Maintains Target Price $7
No Data